Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human placebo-controlled study of DM-199 in healthy adults and adults with type 2 diabetes mellitus
NL-OMON40545Active, not recruiting
- Sponsor
- DiaMedica Therapeutics
- Start
- Apr 2013
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of rinvecalinase alfa in type 2 diabetes mellitus (T2DM) (10 arms), sponsored by DiaMedica Therapeutics. Primary endpoints: Safety and tolerability, Serum and fasting glucose safety monitoring and 2 more. Started Apr 2013; status: active, not recruiting.
02
Drugs
rinvecalinase alfa
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON40545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40545.